Search Results
Aug 31, 2026, 06:00 ET Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
chemotherapy, for the first-line treatment of adults with HER2+ (IHC 3+ and IHC 2+/ISH+) unresectable locally advanced or metastatic GEA, and Ziihera in combination with chemotherapy in the same setting for patients with HER2+ (IHC 3+) disease. Jazz has submitted these data for presentation
More news about: Jazz Pharmaceuticals plc
Aug 26, 2026, 14:52 ET Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
actionable insights to support personalised treatment approaches.The PATHWAY HER2 (4B5) test is the most widely adopted HER2-immunohistochemistry (IHC) primary antibody globally,7 achieving consistently high proficiency assessment scores,7 and demonstrating high concordance with
More news about: Roche
Aug 25, 2026, 10:00 ET U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+). "This approval is a major step forward for people with HER2+ advanced GEA.
More news about: Jazz Pharmaceuticals plc
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) with CLDN18.2 IHC 1+ ≥ 1%; and the pivotal Phase III CLINCH‑3 study evaluating ATG-022 monotherapy for GC/GEJC patients with CLDN18.2 IHC 2+ ≥ 20%. We are confident in the potential of ATG-022 to benefit a broad population of
More news about: Antengene Corporation Limited
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
ADC）Latest data from the Phase II CLINCH study: As of June 26, 2026, among patients with moderate to high CLDN18.2 expression (IHC 2+ ≥ 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 42.4% (14/33) and the disease control rate (DCR) was 90.9% (30/33),
More news about: Antengene Corporation Limited
Aug 17, 2026, 10:30 ET Cancer Diagnostics Market worth $44.92 billion by 2031 - Exclusive Report by MarketsandMarkets™
Healthcare providers are increasingly utilizing next-generation sequencing (NGS), polymerase chain reaction (PCR)-based assays, immunohistochemistry (IHC), in situ hybridization (ISH), liquid biopsy, tissue biopsy, tumor biomarker testing, and digital pathology platforms to enhance diagnostic accuracy,
More news about: MarketsandMarkets
Aug 12, 2026, 10:01 ET Cancer Tumor Profiling Market worth $19.87 billion by 2031 - Exclusive Report by MarketsandMarkets™
brain and central nervous system, head and neck, gastrointestinal, pancreatic, liver, and biliary tract cancers. The increasing use of broad NGS panels, IHC-based biomarkers, and blood-based profiling in advanced solid tumors continues to support the dominance of this segment.Tissue samples accounted
More news about: MarketsandMarkets
Aug 06, 2026, 09:15 ET CellCarta Adds Tempus to CDx Commercialization Lab Network
validates the CDx, generates the analytical and clinical evidence package, supports regulatory submissions, and performs centralized immunohistochemistry (IHC) and tissue-based testing. For sponsors within the CellCarta CDx Commercialization Lab Network, Tempus will support provider test ordering through Tempus
More news about: CellCarta
Aug 04, 2026, 07:00 ET Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ --
More news about: Labcorp
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The
More news about: Kelun-Biotech
Jul 30, 2026, 05:06 ET 邁向晚期TNBC一線治療！蘆康沙妥珠單抗(sac-TMT)第六項NDA獲受理
部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-)BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項BTD。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物
More news about: 科倫博泰
Jul 22, 2026, 09:00 ET Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges
pathologist workflows.BenchMark ULTRA PLUS system: A fully automated slide-staining platform utilizing an advanced workflow for immunohistochemistry (IHC) and in situ hybridization (ISH) to reduce manual touchpoints and improve turnaround times.Expanding access to point-of-care solutionsHighlighting
More news about: Roche
Jul 20, 2026, 00:30 ET More Than 60 Nations Unite as IIHM Launches GAIHEC, the World's First Global AI Hospitality Education Council
international collaborations and NamAIste Hospitality GPT.Prof. David Foskett OBE MBE, Chairman of the International Hospitality Council (IHC), UK said:The past, no matter how glorious, must not get in the way of the future—and the future is AI. Artificial Intelligence is another
More news about: International Institute of Hotel Management (IIHM)
Jul 15, 2026, 08:45 ET CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
phenotyping, TME biomarker formation from H&E, cell- and subcellular-level IHC quantification, and H&E-based molecular state prediction.Mindpeak is the frontier tissue-AI partner for precision oncology, turning IHC, H&E, and mIF images into reproducible, quantitative insights - from
More news about: CellCarta
Jul 14, 2026, 20:00 ET 全球首個ADC+IO對比免疫聯合化療一線治療PD-L1陰性非鱗狀NSCLC III期研究達到主要終點，蘆康沙妥珠單抗聯合帕博利珠單抗有望重塑治療格局
部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-)BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定(BTD)。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2
More news about: 科倫博泰
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The
More news about: Kelun-Biotech
Jul 14, 2026, 08:30 ET Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
PTEN loss through IHC testing brings a new level of precision to treatment selection, helping ensure that the right patients can be matched with biomarker-driven therapies at a critical point in their disease."Key Highlights of Caris PTEN IHC Testing:Expanded IHC Capabilities: Caris
More news about: Caris Life Sciences
Jul 08, 2026, 06:45 ET Rainbowco Perkuat Kapabilitas Solusi Fondasi PLTB Lepas Pantai Berbekal Pengalaman Proyek Global
proyek penting, seperti Huadian 1001, kapal instalasi turbin angin lepas pantai pertama di Tiongkok; kapal pengangkut berat berkapasitas 4.000 ton milik IHC; platform instalasi PLTB lepas pantai Huadian Wenqiang berkapasitas 600 ton; serta kapal operasi dan pemeliharaan PLTB lepas pantai Dolphin 01. Berbagai
More news about: Nantong Rainbow Offshore & Engineering Equipment Co., Ltd.
Jul 07, 2026, 08:21 ET Rainbowco amplía sus capacidades en cimentaciones para parques eólicos marinos con una trayectoria de entrega global comprobada
emblemáticas, como el Huadian 1001, el primer buque de instalación de parques eólicos marinos de China; el buque de elevación pesada de 4.000 toneladas de IHC; la plataforma de instalación de parques eólicos marinos Huadian Wenqiang de 600 toneladas; y el buque de operación y mantenimiento de parques eólicos
More news about: Nantong Rainbow Offshore & Engineering Equipment Co., Ltd.
Jul 07, 2026, 08:17 ET Rainbowco mở rộng năng lực sản xuất nền móng điện gió ngoài khơi dựa trên kinh nghiệm triển khai và bàn giao trên toàn cầu
kỹ thuật ngoài khơi mang tính dấu mốc, bao gồm Huadian 1001, tàu lắp đặt điện gió ngoài khơi đầu tiên của Trung Quốc; tàu cẩu hạng nặng 4.000 tấn của IHC; nền tảng lắp đặt điện gió ngoài khơi Huadian Wenqiang 600 tấn; và tàu vận hành, bảo trì điện gió ngoài khơi Dolphin 01. Những dự án này tiếp tục củng
More news about: Nantong Rainbow Offshore & Engineering Equipment Co., Ltd.
Jul 07, 2026, 07:17 ET Rainbowco erweitert seine Kompetenzen im Bereich Offshore-Windkraft-Fundamente dank bewährter globaler Projektabwicklungserfahrung
wegweisender Offshore-Anlagen beteiligt, darunter „Huadian 1001", Chinas erstes Offshore-Windkraft-Installationsschiff; das 4.000-Tonnen-Schwerlastschiff von IHC; die 600-Tonnen-Offshore-Windkraft-Installationsplattform „Huadian Wenqiang" sowie das Offshore-Windkraft-Betriebs- und Wartungsschiff „Dolphin 01".
More news about: Nantong Rainbow Offshore & Engineering Equipment Co., Ltd.
Jul 02, 2026, 10:46 ET Global DNA Diagnostics Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight
strategic acquisition strengthens Agilent's Life Sciences and Diagnostics Markets unit by adding specialized tissue diagnostics, immunohistochemistry (IHC), and molecular pathology products to its portfolio.In February 2026, New England Biolabs (NEB) launched the Monarch® Mag Cell-free DNA
More news about: DelveInsight Business Research, LLP
Jun 29, 2026, 15:26 ET Borr Drilling Limited - Completion of Previously Announced Consent Solicitation and Tender Offer and Redemption of Remaining Senior Secured Notes due 2028 and 2030
Limited (NYSE: BORR) (OSE: BORR) ("Borr Drilling" or the "Company") today announced the final tender results of the previously announced offer by Borr IHC Limited (the "Issuer"), the Company's wholly-owned subsidiary, to purchase for cash (the "Tender Offer") (i) any and all of its outstanding 10.000% Senior
More news about: Borr Drilling Limited
Jun 22, 2026, 09:06 ET 蘆康沙妥珠單抗聯合奧希替尼一線治療EGFR突變NSCLC轉化研究成果刊發於《Cancer Cell》
EGFR突變陽性局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI單藥治療後進展的EGFR突變陽性局部晚期或轉移性非鱗狀NSCLC；4)既往接受內分泌治療且晚期階段至少接受過一線化療的不可切除或轉移性激素受體陽性(HR+)、人表皮生長因子受體2陰性（HER2-，免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-) BC。上述前兩項適應症已納入中國國家醫保藥品目錄(NRDL)，有望為更多BC和NSCLC患者帶來具有臨床意義的生存獲益。同時，sac-TMT已獲中國國家藥品監督管理局(NMPA)授予六項突破性療法認定(BTD)。sac-TMT是全球首個在肺癌適應症領域獲批上市的TROP2
More news about: 科倫博泰
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The
More news about: Kelun-Biotech